- Residency - Einstein Medical Center (2011-2014), Internal Medicine
- Fellowship - Sidney Kimmel Medical College (2014-2017), Hematology Oncology
- Medical School - Medical College University of Kerala (2000-2007)
- Graduate School - University of Texas at Dallas (2022-2024)
Praveen Ramakrishnan, M.D.
- Internal Medicine - Hematology/Oncology
- Lymphoma Treatment
- Cellular Therapy
New Patient Appointment Accepting Virtual Visits or 214-645-4673
Biography
Praveen Ramakrishnan, M.D., M.S., M.B.A., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology and Oncology. Dr. Ramakrishnan serves as the Director of the Aggressive Lymphoma Program and he specializes in treating lymphoma and other hematologic malignancies. In addition, Dr. Ramakrishnan serves as the Medical Director of the Infusion Center and Acute Care Center (SAC) at Harold C. Simmons Comprehensive Cancer.
Originally from India, Dr. Ramakrishnan received his initial medical training at the Medical College University of Kerala, India. He completed internal medicine residency training at the Jawaharlal Institute of Medical Education and Research in Puducherry, India. Drawn by the opportunity for the integration of clinical medicine, hematologic malignancies, and stem cell transplantation, he completed advanced training in hematology and medical oncology at the Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, where he also earned a master's degree in pharmacology through the NIH K30 Training Program in Human Investigation.
Certified by the American Board of Internal Medicine in internal medicine and in hematology and medical oncology, he joined the UT Southwestern faculty in 2017.
Dr. Ramakrishnan's research interests include developing targeted and cellular therapies for treating patients with lymphomas.
Dr. Ramakrishnan is an active member of several professional organizations, including the American College of Physicians, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, American Society for Blood and Marrow Transplantation, American Association for Cancer Research, American Association for the Advancement of Science, and the International Primary CNS Lymphoma Collaborative Group.
Personal Note
Dr. Ramakrishnan’s interests outside of medicine include reading, watching movies, traveling, and quizzing. During his residency training, he was a three-time national champion at the American College of Physicians' Doctor's Dilemma competition.
Education & Training
Professional Associations & Affiliations
- American Medical Association (2011), Member
- American College of Physicians (2011), Member
- American Society for Clinical Oncology (2013), Member
- American Society for Hematology (2014), Member
- Indo-American Cancer Association (2015), Member
- American Society for Blood and Marrow Transplantation (2015), Member
- American Association for the Advancement of Science (2016), Member
- American Association for Cancer Research (2016), Member
- Texas Medical Association (2017), Member
- Dallas County Medical Society (2017), Member
Honors & Awards
- Dr. Chandrasekar Memorial Gold Medal - Best Outgoing Post Graduate, Internal Medicine 2010, Jawaharlal Institute of Postgraduate Medical Education and Research, India
- Certificate of Merit for First Prize 2012, ACP National Doctors Dilemma Competition (Medical Jeopardy) New Orleans, LA
- Sonia Stupniker, M.D. Award for Outstanding Achievement in Scholarly Activity 2014, Albert Einstein Medial Center Convocation, Philadelphia, PA
- Gold Medal, Best Research Dissertation 2010, Jawaharlal Institute of Postgraduate Medical Education and Research, India
- Gold Medals in Obstetrics and Gynecology, Physiology, and Biophysics 2005, Government Medical College, University of Kerala, India
- Gold Medals in Cardiology, Neurology, and Internal Medicine 2010, Jawaharlal Institute of Postgraduate Medical Education and Research, India
Books & Publications
-
Publications
-
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M, Cancer 2020 Feb -
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Ghosh N, Ahmed S, Ahn KW, Ramakrishnan P, et al. JAMA Oncology 2020 7 6 1011-1018 -
Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies.
Mahimainathan L, Narasimhan M, Corchado R, Patel H, Kansagra A, Devaraj S, Ramakrishnan Geethakumari P, Muthukumar A. Diagnostics 2020 12 10 992 -
A Radiomic Machine Learning Model to Predict Treatment Response to Methotrexate and Survival Outcomes in Primary Central Nervous System Lymphoma
Ali O, Nalawade S, Xi Y, Wagner B, Mazal A, Ahlers S, Rizvi S, Awan F, Kumar K, Desai NB, Maldjian JA, Pinho M, Ramakrishnan Geethakumari P Blood 2020 136 Supplement 1 29-30 -
CAR T-cell Therapy in Relapsed/ Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A ?Real-World? Analysis of Patterns of Failure and Role of Bridging Therapy
Ravella R, Ramakrishnan Geethakumari P, Kumar K, et al. Blood 2020 136 Supplement 1 22-23 -
Comparison of Demographics, Treatment Patterns and Outcomes among Primary Central Nervous System Lymphoma (PCNSL) Patients Treated at a Safety-Net Hospital versus a Tertiary Academic Institution within the same Healthcare System
Patel A, Ali O, Kainthla R, Rizvi S, Awan F, Desai NB, Timmerman R, Kumar K, Ramakrishnan Geethakumari P Blood 2020 136 Supplement 1 11-12 -
An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR, Awan F. Expert Rev Hematol 2020 13 10 1039-1046 -
Breast Implant-associated Plasmablastic Lymphoma: A Case Report and Discussion of the Literature.
Geethakumari PR, Markantonis J, Shah JL, Alsuwaidan A, Shahab I, Chen W, Jaso JM, Clinical lymphoma, myeloma & leukemia 2019 Jun -
MYC Partner Matters: MYC-IGH is Associated with Inferior Survival in De Novo High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
Chaudhry R, Alsuwaidan A, Ramakrishnan Geethakumari P, Chen et al. Laboratory Investigation - Nature 2019 99 March 1 -
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis
Epperla N, Ahn KW, Litovich C, Ramakrishnan P, Fenske TS, Hamadani M, et al. Journal of Hematology & Oncology 2019 12 -
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M Cancer 2018 Apr -
Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome.
Geethakumari PR, Leiby B, Nair R, Alpdogan SO, Carabasi M, Filicko-O'Hara J, Gaballa S, Kasner M, Klumpp T, Martinez-Outschoorn U, Palmisiano N, Wagner JL, Porcu P, Flomenberg N, Grosso D, Bone marrow transplantation 2017 10 52 10 1465-1467 -
PARP Inhibitors in Prostate Cancer.
Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK Current treatment options in oncology 2017 Jun 18 6 37 -
Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome.
Geethakumari PR, Mille P, Gulati R, Nagalla S Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2017 Mar -
The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.
Chae YK, Gagliato Dde M, Pai SG, Carneiro B, Mohindra N, Giles FJ, Ramakrishnan-Geethakumari P, Sohn J, Liu S, Chen H, Ueno N, Hortobagyi G, Gonzalez-Angulo AM PloS one 2016 11 4 e0152585 -
Increasing colon cancer screening in primary care among African Americans.
Myers RE, Sifri R, Daskalakis C, DiCarlo M, Geethakumari PR, Cocroft J, Minnick C, Brisbon N, Vernon SW Journal of the National Cancer Institute 2014 Dec 106 12 -
Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge.
Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, Daver N Clinical lymphoma, myeloma & leukemia 2014 Aug 14 4 e115-8 -
Genetic analysis of OCT1 gene polymorphisms in an Indian population.
Umamaheswaran G, Praveen RG, Arunkumar AS, Das AK, Shewade DG, Adithan C Indian journal of human genetics 2011 Sep 17 3 164-8
-
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Research
- Lymphoma Research
- Targeted Therapy
- Immuno-Oncology
- Cellular Therapy
- Stem Cell Transplantation
- Hematologic Malignancies
Clinical Focus
- Lymphoma Treatment
- Cellular Therapy
- Targeted Therapy
- Bone Marrow Transplant
- Rare and Orphan Hematologic Disorders
- Histiocytic Disorders
- Malignant Hematology
- Ocular Lymphoma
Results: 1 Locations
Blood Cancers/Transplant and Cellular Therapies Clinic
at Cancer Care Outpatient Building 6202 Harry Hines Blvd., 6th FloorDallas, Texas 75235 (214) 645-4673 Directions to Blood Cancers/Transplant and Cellular Therapies Clinic at Cancer Care Outpatient Building, Dallas Parking Info for Blood Cancers/Transplant and Cellular Therapies Clinic
New Patient Appointment Accepting Virtual Visits or 214-645-4673